There's no shortage of cancer immunotherapies trying ... Sanofi and Regeneron have reported new data for Libtayo that suggests the drug could be a contender. Overall survival (OS) was 22 months ...

Sanofi and Regeneron's latecomer checkpoint inhibitor Libtayo has largely been protected ... but so far there's been no breakdown of how the drug performed by type. That will likely have to ...